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Background
Conventional and atypical antipsychotics are widely used
in the treatment of Bipolar Disorder. Switches between
antipsychotic medications often occur for several reasons
– mostly due to adverse events or lack of efficacy. BIRDird
(Bipolar dDisorder Retrospective Data) was conducted to
document the experience with conventional and atypical
antipsychotics in Greek patients with bipolar disorder and
to investigate the effects of switching their antipsychotic
medication to atypical antipsychotics.
Materials and methods
In this retrospective survey, data from patients with bipo-
lar disorder whose previous antipsychotic medication –
conventional or atypical – had been switched to atypical
antipsychotics within the last 12 months were investi-
gated. CRFs from 300 patients in private and state clinics
across Greece were evaluated. Information was collected
on demographics, patient history, diagnosis, comorbidi-
ties, side effects and clinical global impression three
months prior to, at the time and three months following
switching. Effects of medication on Patients Global Con-
dition (PGC) could be scored as "very much improved",
"much improved", "minimally improved", "no change",
"minimally worse", "much worse" or "very much worse".
As the primary goal of this study was descriptive, no sam-
ple size has been calculated; data were descriptively ana-
lyzed.
Results
Patients had mean age of 40.7 years and mean period
between onset of disorder and current diagnosis was 3
years. 80% of 240 evaluable patients (240 out of 300,
80%) had a diagnosis of Bipolar Disorder I, 51 (17%)
Bipolar II, 3 (11%) cyclothymic and 6 (2%) NOS. 175
(58%) of the patients switched from conventional to atyp-
icals and 125 (42%) switched between atypicals. In both
groups patients switched mainly to risperidone (75%)
and olanzapine (16%).
Improvement on PGC CGI scores was observed in the
71% most of the patients: in 75% of patients switching
between atypicals antipsychotics and in 68% of patients
switching from a conventional to an atypicals. Respec-
tively, "no change" was observed in 27% of the patients:
in 23% of switches between atypicals and in 29% from
conventional to atypical; finally, worsening as observed in
from International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour
Thessaloniki, Greece. 17–20 November 2005
Published: 28 February 2006
Annals of General Psychiatry 2006, 5(Suppl 1):S301 doi:10.1186/1744-859X-5-S1-S301
<supplement> <title> <p>International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/conte t/files/pdf/1744-859X-5-S1-full.pdf">here</a>.</note> </supplement>Page 1 of 2
(page number not for citation purposes)
Annals of General Psychiatry 2006, 5:S301Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
3% of the patients: 2% between atypicals and in 3% from
conventional to atypical.
Main reasons for switching were adverse events and "lack
of efficacy". Side effects was the main reason for switch-
ing, with "weight gain" most frequently mentioned in the
atypical group and EPS most frequently mentioned in the
conventional group.
Discussion
In this retrospective study, the switch of antipsychotic
medication to an atypical drug for the treatment of Bipo-
lar Disorder was associated with a clinical improvement
in 71% of the patients as assessed by the PGCaccording
CGI scores.
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